ARTICLES

In the world of hype surrounding the term ‘Artificial intelligence’ (AI), it’s natural to ask how you can actually define what AI is (and isn’t). With many tech providers offering genuinely innovative and valuable solutions under the banner of AI, whilst others use...

We're excited to share our comprehensive whitepaper on Antibody-Drug Conjugates (ADCs), a groundbreaking class of targeted cancer therapies. Dive into the details and discover how ADCs are revolutionising oncology.  Here are some of the key highlights:  Mechanism of...

Many pharma companies are setting up their AI chatbot systems to interrogate their data, but many clients may not know how to make the most of them.    In our recent webinar, Branding Science Senior Data Scientist, Gabe Musker, and Vice President of Strategic...

The importance of the role that caregivers play in the healthcare landscape cannot be overstated.  Caregivers are playing an even greater role in the patient journey, and the rise in cancer and other chronic diseases means there are now more caregivers than ever. ...

6% of people around the world are affected by any of the 7,000+ rare diseases, but only 5% of rare diseases have an approved treatment People living with rare diseases undergo a long, arduous and uncertain journey to find, if at all, an appropriate treatment for their...

Brand planning is a vital but much maligned part of pharmaceutical marketing.    All too often, it’s seen as a chore, a box ticking exercise, or something to get done and move on from. The reality couldn’t be further from this!   In a recent webinar, Branding Science...

The pharmaceutical insights industry has used fundamentally the same questions for a long time in our research to support pipeline decisions and planning. Questions like: How likely are you to use this product? What percentage of patients would you use it for? Is it...

Much of market research still relies on self-reported answers. We ask people questions and assume they can accurately describe how they go about making decisions - and typically also that they rationally consider all the factors before doing so. These are not...

At Branding Science, we regularly work with market access teams and are well attuned to the complex challenges they face.  So, what are the core problems that global and regional market access teams encounter when working to deliver their global access targets? ...

You might find this controversial, confirmatory or somewhere in between, but here are our 10 immutable ‘laws’ of pharmaceutical brand planning: 1. Most teams see brand planning as a chore Team members have other things to do (or that they would rather do) and brand...